Jeremy Grantham's NBIX Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 35,626 shares of Neurocrine Biosciences, Inc. (NBIX) worth $4.69 M, representing 0.01% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Jeremy Grantham has initiated a new position in NBIX, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 28,493 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +28,493 | Add 399.45% | 35,626 | $131.74 |
| Q4 2025 | +7,133 | New Buy | 7,133 | $141.83 |
Jeremy Grantham's Neurocrine Biosciences Investment FAQs
Jeremy Grantham first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2025, acquiring 7,133 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Neurocrine Biosciences, Inc. (NBIX) for 2 quarters since Q4 2025.
Jeremy Grantham's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q1 2026, adding 35,626 shares worth $4.69 M.
According to the latest 13F filing for Q1 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 35,626 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $4.69 M.
As of the Q1 2026 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.01% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 35,626 shares, as reported at the end of Q1 2026.